Products
Cevostamab Biosimilar Bispecific Antibody (FCRL5 × CD3) for Research
Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-103-1mg | 1mg | |
| GMP-Bios-ab-103-10mg | 10mg | |
| GMP-Bios-ab-103-100mg | 100mg | |
| GMP-Bios-ab-103-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody |
| INN Name | Cevostamab |
| Target | FCRL5;CD3 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - FCRL5
1. Protein Fc receptor-like protein 5
2. Gene FCRL5
3. Organism Homo sapiens (Human)
Function
May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells.
